COVID-19 vaccines: keeping pace with SARS-CoV-2 variants

Muge Cevik; Nathan D. Grubaugh; Akiko Iwasaki; Peter Openshaw

doi:10.1016/j.cell.2021.09.010

COVID-19 vaccines: keeping pace with SARS-CoV-2 variants

Muge Cevik, Nathan D. Grubaugh, Akiko Iwasaki, Peter Openshaw

Research output: Contribution to journal › Comment/debate

Abstract

As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.

Original language	English
Journal	Cell
DOIs	https://doi.org/10.1016/j.cell.2021.09.010
Publication status	Published - 16 Sept 2021

Keywords

COVID-19

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cell.2021.09.010

Cite this

@article{8469b27c55194579b1aa9e3c7423220c,

title = "COVID-19 vaccines: keeping pace with SARS-CoV-2 variants",

abstract = "As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.",

keywords = "COVID-19",

author = "Muge Cevik and Grubaugh, {Nathan D.} and Akiko Iwasaki and Peter Openshaw",

year = "2021",

month = sep,

day = "16",

doi = "10.1016/j.cell.2021.09.010",

language = "English",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

}

TY - JOUR

T1 - COVID-19 vaccines

T2 - keeping pace with SARS-CoV-2 variants

AU - Cevik, Muge

AU - Grubaugh, Nathan D.

AU - Iwasaki, Akiko

AU - Openshaw, Peter

PY - 2021/9/16

Y1 - 2021/9/16

N2 - As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.

AB - As the SARS-CoV-2 pandemic evolves, new variants continue to emerge. Some highly transmissible variants, such as Delta, also raised concerns about the effectiveness provided by current vaccines. Understanding immunological correlates of protection and how laboratory findings correspond to clinical effectiveness is imperative to shape future vaccination strategies.

KW - COVID-19

U2 - 10.1016/j.cell.2021.09.010

DO - 10.1016/j.cell.2021.09.010

M3 - Comment/debate

SN - 0092-8674

JO - Cell

JF - Cell

ER -

COVID-19 vaccines: keeping pace with SARS-CoV-2 variants

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this